Cardiff Oncology
CRDF
38 hedge funds and large institutions have $797K invested in Cardiff Oncology in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 9 closing their positions.
0.13% less ownership
Funds ownership: 0.2% → 0.07% (-0.13%)
19% less funds holding
Funds holding: 47 → 38 (-9)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
79% less capital invested
Capital invested by funds: $3.84M → $797K (-$3.04M)
89% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$35.3K |
| 2 |
CGA
Crescent Grove Advisors
Lake Forest,
Illinois
|
+$9.83K |
| 3 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
+$1.73K |
| 4 |
Bank of New York Mellon
New York
|
+$1.28K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.23M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$357K |
| 3 |
Millennium Management
New York
|
-$142K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$116K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$46K |
CRDF Hedge Fund Activity: Q4 2017 in Review
38 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2017, worth a combined $797K — down 79% from $3.84M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CRDF and 1 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Two Sigma Securities, adding an estimated $35.3K. The largest seller was Sabby Management, exiting entirely with an estimated $1.23M sold.
- 38 institutional investors held Cardiff Oncology (CRDF) as of Q4 2017, down from 47 in Q3 2017.
- Funds reported $797K of Cardiff Oncology stock for Q4 2017, down 79% quarter-over-quarter.
- 1 fund opened new Cardiff Oncology positions in Q4 2017 and 9 closed out, a net change of -8 holders.
- The largest Cardiff Oncology buyer in Q4 2017 was Two Sigma Securities, an estimated $35.3K added.
- The largest Cardiff Oncology seller in Q4 2017 was Sabby Management, an estimated $1.23M sold.
Based on aggregated 13F filings for Q4 2017.